FDA-approved monoclonal antibodies blocking immune checkpoints in human cancer
| Target | Therapeutic antibody | Tumor type | FDA approval year |
| CTLA4 | Ipilimumab | Melanoma, renal cell carcinoma, metastatic colorectal cancer | 2011 |
| PD-1 | Pembrolizumab | Melanoma, non-small cell lung cancer, renal cell carcinoma, urothelial bladder cancer, Hodgkin’s lymphoma, head and neck cancer, Merkel cell carcinoma, microsatellite instability-high cancer, gastric cancer, hepatocellular carcinoma, cervical cancer, primary mediastinal large B-cell lymphoma | 2014 |
| Nivolumab | Melanoma, non-small cell lung cancer, renal cell carcinoma, urothelial bladder cancer, Hodgkin’s lymphoma, head and neck cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer | 2014 | |
| Cemiplimab | Cutaneous squamous-cell carcinoma | 2018 | |
| PD-L1 | Atezolizumab | Non-small cell lung cancer, urothelial bladder cancer, small cell lung cancer, breast cancer | 2016 |
| Avelumab | Merkel cell carcinoma, urothelial bladder cancer | 2017 | |
| Durvalumab | Non-small cell lung cancer, urothelial bladder cancer | 2017 |
Data have been acquired from “Timeline of Anti-PD-1/L1 Antibody Approvals by the FDA.” Available in online (https://www.cancerresearch.org/scientists/immuno-oncology-landscape/pd-1-pd-l1-landscape).
IFN-γ, interferon-gamma; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1.